AKT1 and familial dilated cardiomyopathy: Notably, although CEPO demonstrated a dose-dependent effect on DCM in this study, the long-term (8-week) treatment of CEPO failed to demonstrate a significant increase in PI3K (p85) and Akt1 mRNA expression, and did not demonstrate a significant benefit, when compared with the short-term (four-week) treatment.